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Bioﬁlm dispersalDiguanylate cyclases (DGC) and phosphodiesterases (PDE), respectively synthesise and hydrolyse the
secondary messenger cyclic dimeric GMP (c-di-GMP), and both activities are often found in a single
protein. Intracellular c-di-GMP levels in turn regulate bacterial motility, virulence and bioﬁlm
formation. We report the ﬁrst structure of a tandem DGC–PDE fragment, in which the catalytic
domains are shown to be active. Two phosphodiesterase states are distinguished by active site
formation. The structures, in the presence or absence of c-di-GMP, suggest that dimerisation and
binding pocket formation are linked, with dimerisation being required for catalytic activity. An
understanding of PDE activation is important, as bioﬁlm dispersal via c-di-GMP hydrolysis has
therapeutic effects on chronic infections.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Bioﬁlms are the major form of bacterial organisation and are a
common problem in chronic infections [1,2]. For the bacterium
Pseudomonas aeruginosa, chronic infection and bioﬁlm formation
is the main cause of mortality for sufferers of cystic ﬁbrosis [3].
Bioﬁlms display an increased persistence and tolerance to antibiot-
ics [4]. Physiologically, bioﬁlm formation is associated with high
levels of the secondary messenger cyclic dimeric guanosine mono-
phosphate (c-di-GMP) [5,6], which is synthesised by diguanylate
cyclases (DGC) from two guanosine triphosphate (GTP) molecules
[7]. Reduction in c-di-GMP levels can be achieved by NO stimula-
tion, leading to bioﬁlm dispersal, thereby offering new strategies
to treat bioﬁlm-associated infection [8,9].
Bioﬁlm dispersion is linked to c-di-GMP hydrolysis by two types
of phosphodiesterases (PDE) [10] with either an EAL [11] or aHD-GYP [12] motif. The two classes differ with respect to their
hydrolysis products. HD-GYP domains hydrolyse c-di-GMP into
two GMP molecules and have been shown to utilise trinuclear iron
binding [13]. EAL domains, however, hydrolyse c-di-GMP to the
linear di-nucleotide 50-pGpG and additionally require a dimerisa-
tion event for PDE activation [14]. EAL domains have been identi-
ﬁed to contain two key surface helices providing a binding
groove for an antiparallel dimer formation [15,16]. In addition to
the EAL motif, a second conserved DDFGTG(YSS) sequence motif
coordinates the Mg2+ ions required for activity [14]. Domains with
a degenerate DDFGTG and EAL motif are catalytically inactive and
instead function as c-di-GMP sensor proteins [17].
EAL phosphodiesterase domains often occur in tandem with a
diguanylate cyclase domain, in a single protein [18]. A structure
of these dual domain proteins is known from the DGC–PDE c-di-
GMP sensor protein LapD [19]. Conversion to the sensor is
explained by a lack of the conserved EAL and DDFGTG motifs
required for PDE activity. The determination of the structure of
LapD provides insight into the regulation of nucleotide binding,
as the isolated EAL domain can bind c-di-GMP, but in the tandem
domain structure the nucleotide-binding pocket is obstructed.
For proteins with dual activity, the underlying question is how
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controlled.
We have studied the tandem domain protein motility regulator
A (MorA), conserved across Pseudomonas species [20]. Additional to
PDE and DGC domains, the cytosolic segment contains four PAS
sensory domains (Per-Arnt-Sim homology) [21]. The protein is
localised to the membrane by two N-terminal transmembrane
helices and can affect bacterial motility [20]. MorA has been linked
to ﬁmbriae and ﬂagella formation, prerequisites for bioﬁlm forma-
tion and dispersal, respectively [22,23]. The protein is also reported
to control the timing of ﬂagella development and regulate sensory
chemotaxis pathways [20]. The C-terminal PDE domain of MorA
shows intact DDFGTG and EAL motifs, indicative of phosphodies-
terase activity.
Here, we report the catalytic activity and structure of the tan-
dem DGC–PDE fragment from MorA in the absence and presence
of c-di-GMP and two structures of the isolated PDE in absence of
nucleotide, but distinguished by dimerisation. Our data describe
two states of the PDE nucleotide-binding pocket. The four struc-
tures suggest that dimerisation is involved in the formation of
the nucleotide-binding pocket and catalytic activity. Understand-
ing of PDE activation is highly sought after as bioﬁlm dispersal
results in bacteria becoming susceptible to antibiotics.
2. Materials and methods
2.1. Molecular biology and protein puriﬁcation
Genomic DNA of P. aeruginosa PAO1 was isolated using the
DNeasy blood and tissue kit (Qiagen). MorA gene PA4601 was
ampliﬁed by PCR using Phusion Polymerase (Finnzymes); PCR
fragments were restriction digested and inserted into the expres-
sion vector pET-28a (Novagen). The following fragments were
cloned with N-terminal fusion tags: DGC978–1144, PDE145–1409 and
tandem DGC–PDE978–1409. The D1310N/D1311N point mutations
were introduced into tandem DGC–PDE978–1409 using the Lightning
QuikChange kit (Invitrogen).
For recombinant expression of all proteins, BL21 DE3 Escherichia
coli competent cultures were grown in LB medium and induced by
1 mM isopropyl-beta-D-thiogalactopyranoside (Melford) at an
optical density OD600 of 0.6. The cultures were collected after 20 h
growth at 18 C by centrifugation. Cells from2 l cultureswere resus-
pended in 50 ml 50 mM HEPES buffered at pH 7.5 with 300 mM
NaCl, 5% glycerol, lysed by sonication, and centrifuged at
16,000 rpm for 40 min (Beckman Avanti centrifuge, JA25.50 rotor).
The supernatantwas loaded onto 4 ml Ni-NTA resin (Qiagen), equil-
ibrated with buffer A (50 mM HEPES buffered at pH 7.5 with
300 mM NaCl, 2 mM MgCl2, 5% glycerol, 2 mM b-mercaptoethanol
and 20 mM imidazole), followedbywasheswith buffer A containing
80 mM imidazole and elution using buffer A containing 300 mM
imidazole. Following concentration over spin concentrators (Gener-
on), the eluate was loaded onto an S75 16/600 size exclusion col-
umn (GE) equilibrated in 50 mM HEPES buffered at pH 7.5 with
300 mMNaCl, 2 mMMgCl2 and 2 mM b-mercaptoethanol. Fractions
containing the desired protein, conﬁrmed by SDS–PAGE, were
pooled and concentrated using spin concentrators (Generon).
2.2. Enzymatic assay
Activity of MorA fragments was determined by an enzyme
assay followed by HPLC analysis of nucleotides, adapted from
[24]. Enzymes were used at a concentration of 40 lM; these were
mixed with 0.1 mM GTP (Biolog) in 50 mM HEPES buffered at pH
7.5, with 300 mM NaCl, 2 mMMgCl2 and 2 mM b-mercaptoethanol
to 200 ll and incubated at room temperature for 1 h. Samples were
then run on a combination of a C4 and a C18 RPC column (Vydac),using a Shimadzu HPLC system, in buffer A (100 mM KPO4 buffered
at pH 6) with an elution gradient of 15 min into buffer B (70%
buffer A with 30% methanol). Absorbance at 254 nm was used for
detection. The system was calibrated using GTP (Sigma), 50-pGpG
(Biolog) and c-di-GMP, prepared by enzymatic synthesis from
GTP, using puriﬁed YdeH as described in [25].
2.3. Bis-4pNPP analysis
PDE activity was measured in 1 ml total volume containing
0.4 mg/ml protein, 5 mM bis-(p-nitrophenyl) phosphate (Sigma)
and 50 mM Tris pH 9.2 with 5 mM MgCl2 and 50 mM NaCl. The
reaction was carried out at 37 C. After 180 min the absorbance
of the hydrolysed product was measured at 405 nm using a nano-
drop spectrophotometer (Thermo Scientiﬁc). Controls contained
heat inactivated proteins (100 C, 5 min).
2.4. Structure determination and analysis
Puriﬁed proteins were crystallised in sitting drop 96-well plates
using a Gryphon nanodrop dispenser (Art Robbins Instruments).
Crystal hit optimisation was carried out using a Minstrel DT alche-
mist (Rigaku). Data were collected at the Southampton Diffraction
Centre, the Diamond Light Source (DLS, Oxford) and the European
Synchrotron Radiation Facility (ESRF, Grenoble). Data reduction,
molecular replacement and reﬁnement were carried out with
CCP4 [26] and Phenix [27,28]; models were built using Coot [29]
and automated water structure building in ArpWarp [30] (Table 1).
Dyndom was used to determine hinge regions [31]. PISA was used
to calculate protein–protein interfaces [32]. Pymol was used to
create ﬁgures (Schrödinger).
DGC–PDE978–1409 D1310N/D1311Nmutant (PDB 4RNF): crystal-
lised at 21 C and a concentration of 26 mg/ml in 0.12 MMorpheus
alcohols, 0.1 M Buffer System 1, 30% EDO P8K (Molecular Dimen-
sions). Data were collected at DLS I03 to a resolution of 2.85 Å.
The structure was solved by molecular replacement with dimeric
PDE1145–1409 (this study), and the GGDEF domain from Methylococ-
cus capsulatus (PDB 3ICL, [33]).
DGC–PDE978–1409 c-di-GMP complex (PDB 4RNH): crystallised
at 21 C and a concentration of 20 mg/ml and 2 molar excess of
GTP (Sigma) in 0.2 M sodium thiocyanate, 20% w/v PEG 3350. Data
were collected at DLS I04 to a resolution of 2.45 Å. The structure
was solved by molecular replacement using the DGC–PDE978–1409
D1310N/D1311N mutant (this study). Instead of GTP, we obtained
c-di-GMP bound to the active site of the PDE in this crystal form.
Dimeric PDE1145–1409 (PDB 4RNI): crystallised at 21 C and a
concentration of 10 mg/ml and 3 molar excess of 50-pGpG (Biolog)
in 0.1 M Morpheus Buffer System 3, 0.1 M amino acids, 30% GOL
P4K (Molecular Dimensions). Data were collected at DLS I04 to a
resolution of 2.17 Å. The structure was solved by molecular
replacement, using the Thiobacillus denitriﬁcans phosphodiesterase
(PDB 3N3T, [34]). 50-pGpG was not visible in the ﬁnal structure but
required for crystallisation.
Monomeric PDE1145–1409 (PDB 4RNJ): crystallised at 21 C and a
concentration of 12 mg/ml in 0.1 M Morpheus Buffer System 1,
0.09 M NPS, 30% EDO P8K (Molecular Dimensions). Data were
collected at ESRF ID14-1 to a resolution of 2.32 Å. The structure
was solved by molecular replacement with dimeric PDE1145–1409
(this study).
3. Results and discussion
3.1. Activity assay
To conﬁrm that MorA is a suitable system to study bi-functional
c-di-GMP regulation, we ﬁrst ensured that MorA has diguanylate
Table 1
X-ray data collection and reﬁnement statistics.
DGC–PDE978–1409
Mutant D1310/1311N
PDE1145–1409
Dimer c-di-GMP complex
DGC–PDE978–1409
Apo-Monomer
PDE1145–1409
Apo-Dimer
Accession code 4RNF 4RNH 4RNJ 4RNI
Space group
Cell a, b, c (Å)
Angles a, b, c ()
P1
40.7, 47.4, 60.0
82.15, 71.63, 70.66
P3121
81.3, 81.3, 128.0
90, 90, 120
P212121
52.0, 79.8, 138.5
90, 90, 90
P21212
35.6, 94.5, 154.6
90, 90, 90
Resolution (Å)a 28.46–2.85
(3.26–2.85)
61.7–2.45
(2.52–2.45)
48.75–2.32
(2.4–2.32)
77.35–2.17
(2.23–2.17)
Rmerge (%)a 17.4 (59.1) 10.7 (74.6) 7.2 (67.8) 11.0 (78.8)
I/r (I)a 7.4 (2.4) 14.5 (2.6) 13.87 (1.8) 18.3 (3.9)
No. unique reﬂections 9235 18546 25720 28764
Completeness (%)a 98.5 (98.0) 100 (99.5) 99.7 (98.4) 100 (99.8)
Redundancy a 2.8 (2.7) 8.1 (6.3) 4.28 (3.69) 13.3 (13.4)
Reﬁnement
Rwork/Rfree (%) 23.1/27.7 18.7/24.3 19.8/25.3 18.4/23.5
No. protein atoms
No. ligand atoms/ion
No. waters
3332
–
12
3525
(c-di-GMP/Mg2+) 68/4
140
3996
–
121
3961
–
156
Protein Bfactor (Å2)
Ligand/ion Bfactor (Å2)
Water Bfactor (Å2)
36.3
–
52.6
45.3
(c-di-GMP/Mg2+) 54.2/50.4
45.1
42.6
–
28.9
36.9
–
35
Bond lengths rmsd (Å)
Bond angles rmsd ()
0.014
1.370
0.006
0.815
0.013
1.431
0.002
0.860
Ramachandran (%)
Preferred regions
Allowed regions
Outliers
95.96
3.80
0.24
97.58
2.42
0
98.61
1.39
0
98.41
1.59
0
Closest contact Monomer A and symmetry A
(X  1, Y + 1, Z) DG of 5 kJ/mol
with a surface area of 1002.7 Å2
Monomer A and symmetry A (X  Y,
Y, Z-1/3) DG of 14.5 kJ/mol with
a surface area of 1631.6 Å2
Monomer A and B DG of
4 kJ/mol with a surface
area of 776.5 Å2
Monomer A and B DG of
11.6 kJ/mol with a
surface area of 1070.8 Å2
a Values in parentheses are for the highest-resolution bin.
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RPC-HPLC separation of nucleotide products. When an isolated
DGC978–1144 fragment was incubated with GTP, a retention product
at 10 minutes is observed that corresponds to the c-di-GMP stan-
dard (Fig. 1A). This indicates MorA has diguanylate cyclase activity.
To study the bi-functional enzyme, we incubated the MorA
fragment containing both DGC and PDE domains (DGC–
PDE978–1409) with GTP. HPLC analysis of reaction products showed
a peak with a decreased retention time, compared with c-di-GMP
that corresponds to the 50-pGpG standard (Fig. 1A). Since no c-di-
GMP was added in this experiment this indicates MorA’s DGC pro-
duced c-di-GMP, which we observed as a small peak, consistent
with the standard. However, the majority is converted to the linear
nucleotide indicating MorA also has phosphodiesterase activity.
The PDE containing fragments were further tested with the generic
PDE substrate bis-(p-nitrophenyl) phosphate (Table S1), conﬁrm-
ing activity in the PDE domain.
To corroborate the DGC activity in the tandem DGC–PDE frag-
ment, we mutated the PDE domain to obtain a catalytically inactive
variant. To do this, the DDFGTG sequence motif was replaced with
NNFGTG (D1310N and D1311N). The two aspartates that were
replaced coordinate the Mg2+ ions required for activity [14]. HPLC
analysis of reaction products after incubation with GTP showed a
peak that corresponds to the c-di-GMP standard (Fig. 1A). Thus,
the mutant DGC–PDE fragment retained DGC activity but was
unable to produce 50-pGpG, indicating the mutations render the
PDE inactive (Table S1).
The activity assays showed that MorA’s DGC and PDE domains
could synthesise and hydrolyse c-di-GMP respectively. Since MorA
has both, DGC and PDE catalytic activity, it is implicit that MorA
should have mechanisms to control these opposing activities.
Likely mechanisms are either interaction of PDE and DGC domains,
or oligomerisation. Indeed, dimerisation of DGC domains is
required for cyclase activity, as each monomer contributes one
nucleotide to the product, and dimerisation of PDE domains is
known to inﬂuence phosphodiesterase activity [15,16]. Wetherefore investigated the protein fragments for oligomerisation
and initiated structural studies.
3.2. Nucleotide free state of MorA DGC–PDE
To determine the nucleotide free state of the tandem fragment
we used the MorA DGC–PDE978–1409 D1310 and D1311 mutant;
experiments to acquire a nucleotide free structure of the wild type
tandem fragment yielded non-diffracting crystals. The overall
structure of MorA’s DGC–PDE978–1409 mutant is comprised of an
arrangement that separates the DGC and PDE domains into an
open conformation (Fig. 1B and C). A 31 Å long helix (named
H helix, see Section 3.4.), involving 19 amino acid residues
(A1145–L1167), links the DGC and PDE domains. The DGC of MorA
adopts the archetypical GGDEF domain fold that consists of ﬁve
alpha helices surrounding a ﬁve stranded beta sheet (abaabba-
bab) (Fig. 1B) [35]. The DGC is nucleotide free and the nucleotide
recognising helix a2 is disordered. The conformation seen does
not preclude DGC dimerisation. MorA’s PDE forms the canonical
(b/a)8 barrel in which the ﬁrst beta strand is reversed [11], with
respect to classic TIM topology (Fig. 1C) [36]. The open conforma-
tion is stabilised by direct contact between residues K1076 and
E1213 located on the DGC-a4 and PDE-a40 helices (SFig. 1). In
the open conformation, both the PDE and DGC active sites are
accessible.
An interesting feature of the MorA DGC–PDE978–1409 mutant is
the local structure around helix PDE-a5. The PDE-a5 helix in MorA
is extended and consists of residues G1315–Q1324, resulting in the
removal of the DDFGTG motif from the active site, which would be
required for Mg2+ coordination and activity. A nucleotide free
structure of the wild type PDE was determined using the isolated
fragment, PDE1145–1409. Intriguingly, this monomeric PDE1145–1409
structure shows the same features as the MorA DGC–PDE978–1409
mutant with an extended PDE-a5 helix in a Mg2+ free state and
the DDFGTG motif removed from the active site (Fig. 2A). Since
formation of the helix PDE-a5 extension removes catalytic
Fig. 1. Enzymatic activity and crystal structure of the nucleotide free state of MorA tandem DGC–PDE. (A) HPLC analysis of nucleotide loading states after incubation with
GTP; DGC, DGC978–1144; DGC–PDE, DGC–PDE978–1409; DGC–PDEmutant, DGC–PDE978–1409 D1310N/D1311N; standards as indicated; x-axis in minutes, y-axis AU at k = 254. (B)
MorA DGC–PDE978–1409 D1310N/D1311N structure with the DGC domain in orange, the GGDEF sequence motif is highlighted in green. Alpha helices and beta sheets are
labelled. The a2 helix is disordered (dashed line). The H helix (cyan) links the DGC domain to the PDE domain (grey). (C) MorA DGC–PDE978–1409 D1310N/D1311N structure in
different orientation to (B) shows the PDE domain in yellow. The active site DDFGTG motif and the a5 helix or R helix are highlighted in blue, the a6 helix is shown in purple.
The H helix (cyan) links the PDE domain to the DGC domain (grey). Alpha helices and beta sheets are labelled in accordance to classical TIM barrels.
Fig. 2. MorA PDE dimer formation and conformational changes of the R helix. (A) Overlay of monomeric PDE1145–1409 (marine blue) with the dimeric PDE1145–1409 (green). The
two structures differ in the orientation and length of the R helix (PDE-a5). The R helix is extended in the monomeric PDE structure (G1315–Q1324, marine blue) but shorter in
the dimeric PDE structure (L1319–Q1324, green) resulting in different conformations of the DDFGTGYSS motif. Y1389 acts as a gate to the active site and is seen in two
different side chain rotamer conformations. (B) The dimer interface is formed through reciprocal contact of Y1316 and S1317 from monomer A (green) and a symmetry
molecule (X, Y + 1/2, Z + 1/2) (grey). These two residues are part of the DDFGTGYSS motif. The dimeric structure is characterised by a short R helix (a5, L1319–Q1324).
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helix (R helix). It is known that dimerisation regulates PDE activity
and hence we went on to characterise a structure of a PDE dimer to
investigate the nature of this structural rearrangement.
3.3. PDE dimerisation inﬂuences the conformation of the R helix
To promote dimer formation, we crystallised the isolated
PDE1145–1409 domain of MorA in the presence of 50-pGpG. Crystalli-
sation yielded a nucleotide-free dimer with contacts around the
a5-helix (R helix) and the a6 helix (Fig. 2B). PDE domain dimers
have been previously identiﬁed (Table S2) [15–17,19,37,38]. PDE
dimerisation involving PDE-a6 and the R helix has implicationsfor active site formation. The PDE dimer contact between residues
Y1316 and S1317 stabilises the loop formed by residues G1315–
S1318 and thus stabilises a state in which the R helix is shortened
(L1319–Q1324) (Fig. 2A). The shorter conformation of the R helix is
consistent with the previously solved catalytically active c-di-GMP
bound structure from T. denitriﬁcans phosphodiesterase (PDB
3N3T). An extended R helix (G1315–Q1324), as seen in the nucle-
otide-free structures, is not compatible with dimer formation, as it
would lead to clashes around the dimer interface and not allow
residues Y1316 and S1317 of the 1310DDFGTGYSS1318 motif to con-
tribute to dimer formation. Conservation of the YS residues is,
therefore, explained by their involvement in PDE dimerisation
(Fig. 2).
Fig. 4. The role of amino acids in the DDFGTGYSS motif. The side chains of two
aspartate residues (DD) are involved in Mg2+ coordination and the side chains of the
tyrosine/serine residues (YS) are involved in PDE dimerisation.
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DDFGTGYSS motif into an extended loop conformation. However,
no nucleotide or Mg2+ are present in the active site. The dimeric
PDE1145–1409 structure is presumably observed post-hydrolysis,
where the product 50-pGpG has left the binding site. To understand
the signiﬁcance of the different R helix conformations, we wanted
to study the nucleotide-bound state of the PDE within MorA.
3.4. Nucleotide bound state of MorA DGC–PDE
To obtain the c-di-GMP complex, we had to mix the tandem
DGC–PDE978–1409 wild type fragment with excess GTP immediately
before crystallisation. Binding of c-di-GMP into the native PDE
active site of MorA results in PDE dimerisation of the tandem
fragment (Fig. 3A). The orientation of PDE dimer is similar to the
one observed within the isolated PDE1145–1409 structure in the
presence of 50-pGpG (Fig. 2 and Table S2). The DGC domains in this
dimer do not interact with one another (Fig. 3B).
In the nucleotide-bound form the R helix adopts the shorter
conformation (L1319–Q1324), compared to the wild type nucleo-
tide free monomeric PDE (G1315–Q1324) (Fig. 3C). The shorter
conformation of the R helix allows the extended loop conformation
of the DDFGTG motif to contribute to active site formation, where
residues D1310 and D1311 of the DDFGTG motif, along with resi-
due E1189 of the EAL motif coordinate two Mg2+ ions (Fig. 3C
and SFig. 2). Interpretation of this c-di-GMP complex is that of a
Michaelis complex that has yet to undergo activation [8], as theFig. 3. Crystal structure of the dimeric form of MorA DGC–PDE. (A) Structure of the
PDE1145–1409 dimer (Fig. 2 and Table S2). Monomer A is coloured light-blue, the symmetr
DGC domains are not interacting in this dimer. (C) Overlay of the two different PDE states
blue) and the nucleotide-bound DGC–PDE978–1409 structure in the dimeric state (light-b
structure of the catalytic DDFGTGmotif. In the repressed state the aspartates of the DDFG
extended loop that allows the residues to engage Mg2+ and substrate.tandem DGC–PDE is able to hydrolyse c-di-GMP to 50pGpG
(Fig. 1A).
Comparison of the PDE domains presented here allows for an
assignment of two distinct states (Figs. 3C and 4). The nucleo-
tide-free structures show the repressed state with an incomplete
active site, characterised by an extension of the R helix (PDE-a5),
which removes the DDFGTG motif from the active site and results
in the loss of Mg2+ binding. This state is different to the dimeric
state of the PDE1145–1409 and c-di-GMP bound DGC–PDE, where a
shorter R helix is formed. Interactions at the dimeric interfaceDGC–PDE978–1409 c-di-GMP complex forms a PDE dimer, similar to the isolated
y mate (XY, Y, Z + 2/3) is shown in light-orange. (B) Fig. 3A rotated by 30. The
determined: monomeric PDE1144–1409 in the nucleotide free repressed state (marine
lue). The Repressor helix, PDE-a5, changes in orientation and length, affecting the
TGYSS motif are removed from the active site, in the dimeric state the motif forms an
4636 C.W. Phippen et al. / FEBS Letters 588 (2014) 4631–4636stabilise the DDFGTGYSS motif into an extended loop conformation
that allows the aspartates of the DDFGTG motif to bind Mg2+ and
contribute to active site formation. A further difference is observed
with respect to the residue Tyr1389 that acts as a gate to the active
site and is involved in base stacking of one of the c-di-GMP guano-
sine moieties (Figs. 2A and 3C).
When the nucleotide-free DGC–PDEmutant and the nucleotide-
bound DGC–PDE structures are compared, a slight rotation of 20 is
observed between the DGC and PDE domains (SFig. 4). The rotation
suggests that a hinge, located on the H helix (hinge), links the DGC
and PDE domains. This hinge is located on the EAL domain side.
Other orientations of the two domains might be possible.
4. Conclusion
The tandem DGC–PDE MorA structure represents the ﬁrst
structure determined for a dual active DGC and PDE enzyme. From
comparison of the four structures determined, we provide evi-
dence of a conformational change occurring around the R helix
(PDE-a5) of the PDE domain that can repress catalytic activity by
removing the DDFGTG motif form the active site. We show how
the conserved YS residues of the DDFGTGYSS motif are involved
in PDE dimerisation to promote structural changes that enable
the enzyme to bind c-di-GMP. Dimer interactions favour a short-
ened R helix and allow the two catalytic aspartates of the
DDFGTGYSS motif to enter the active site. Regulation of PDE activ-
ity must now be put in the context of protein dimerisation. The
challenge is to understand the inﬂuence of MorA domains outside
the DGC–PDE, such as the transmembrane localisation or the PAS
domains. A deciphering of the further regulatory mechanisms
within MorA and other tandem DGC–PDE proteins is essential for
the development of drugs that tackle bioﬁlm formation and to
understand the regulation of bacterial virulence.
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